This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic ...

Bristol-Myers Squibb shares rose in premarket trade on Friday after the Food and Drug Administration approved a schizophrenia ...

Fiscal fourth-quarter revenue at Costco misses analysts’ estimates, Bristol Myers surges after the FDA approves an oral ...

Given its better valuation, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pick than its peer – ...

Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than ...

The twice-daily pill, Cobenfy, is a badly needed new treatment option for the nearly 3 million adults in the U.S. living with ...

Bristol Myers obtained the drug Cobenfy, also known as KarXT, through its $14 billion takeover of Karuna Therapeutics last ...

An FDA advisory panel on Bristol Myers Squibb Opdivo and Merck Keytruda will examine if PD-L1 tumor expression should limit ...

Shares of Bristol Myers Squibb Co. BMY rallied 1.86% to $50.94 Tuesday, on what proved to be an all-around favorable trading ...

Analyst Chris Shibutani from Goldman Sachs reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report) and keeping the price ...

The US FDA has approved Bristol Myers Squibb’s oral medicine, Cobenfy, for treating schizophrenia in adults. This is the ...

Shares jumped 6% in premarket trading after the Food and Drug Administration approved a treatment for [schizophrenia patients]( ...